4 Results for "

UWB1.289

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "UWB1.289" in MCE Product Catalog:

Cat. No.: HY-155993
CAS No.: 3032451-66-1
Purity:  99.39%
Target:  

PARP

Research Areas:  

Cancer

YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .
loading...
    loading...
Cat. No.: HY-150765
Target:  

PARP Apoptosis

Research Areas:  

Cancer

PARP1-IN-12 is a potent PARP1 inhibitor with an IC50 of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in BRCA-deficient cells .
loading...
    loading...
Cat. No.: HY-181664
Target:  

PARP Apoptosis Caspase

Research Areas:  

Cancer

YCH3971 is a PARP1 inhibitor with a PARP1 IC50 of 7.52 nM and a PARP1 EC50 of 67.75 nM. YCH3971 inhibits the proliferation of BRCA-deficient tumor cells. YCH3971 induces DNA damage, G2/M phase arrest, and caspase-mediated Apoptosis in triple-negative breast cancer cells. YCH3971 can be used for the research of BRCA-deficient tumors .
loading...
    loading...
Cat. No.: HY-171171
CAS No.: 2649242-85-1
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

NERx 329 is a replication protein A (RPA) inhibitor with an IC50 of 4.9 μM. NERx 329 blocks the interaction between RPA and single-stranded DNA, and induces functional RPA depletion, loss of single-stranded DNA gap protection, chromosome fragmentation and cell death. NERx 329 inhibits the DNA damage response signaling pathway, exhibits broad single-agent anticancer activity, and enhances the activity of DNA-damaging agents. NERx 329 can be used in research related to brca1-deficient breast cancer, non-small cell lung cancer, and brca1-deficient ovarian cancer .
loading...
    loading...